Journey Medical (DERM) Asset Writedowns and Impairment (2020 - 2026)
Journey Medical (DERM) posted Asset Writedowns and Impairment of $30000.0 for Q1 2026, up 173.17% on a QoQ basis from -$41000.0 in Q4 2025, and down 84.62% year-over-year from $195000.0 in Q1 2025.
Journey Medical (DERM) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Journey Medical's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $30000.0 for Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 84.62% year-over-year to $30000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$376000.0 (down 153.33% YoY) and the FY2025 annual result came in at -$211000.0, down 140.89% from the prior year.
- Asset Writedowns and Impairment was $30000.0 for Q1 2026 at Journey Medical, up from -$41000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $3.1 million in Q2 2023 and bottomed at -$441000.0 in Q2 2025.
- A 5-year average of $218764.7 and a median of $31000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment soared 10038.71% — and 2024, when it tumbled 613.95%.
- Journey Medical's Asset Writedowns and Impairment stood at $274000.0 in 2022, then sank by 115.69% to -$43000.0 in 2023, then tumbled by 613.95% to -$307000.0 in 2024, then soared by 86.64% to -$41000.0 in 2025, then soared by 173.17% to $30000.0 in 2026.
- Business Quant data shows DERM's Asset Writedowns and Impairment at $30000.0 in Q1 2026, -$41000.0 in Q4 2025, and $76000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Journey Medical | 172.98 Mn | 145.76 Mn | 9.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | -41,000.00 |
| Dec 31, 2025 | -41,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Jun 30, 2025 | -441,000.00 |
| Jun 30, 2025 | -441,000.00 |
| Mar 31, 2025 | 195,000.00 |
| Mar 31, 2025 | 195,000.00 |
| Dec 31, 2024 | -307,000.00 |
| Dec 31, 2024 | -307,000.00 |
| Sep 30, 2024 | 671,000.00 |
| Sep 30, 2024 | 671,000.00 |
| Jun 30, 2024 | 146,000.00 |
| Jun 30, 2024 | 146,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | -43,000.00 |
| Dec 31, 2023 | -43,000.00 |